Although CD20 expression on CLL cells is higher than that of CD19, the CD16/CD19/CD22 construct has been more effective than rituximab in targeting CLL cells, suggesting that simultaneous targeting of CD22 and CD19 is advantageous [246]. Here, FCGR3A is linked to B-cell chronic lymphocytic leukemia.